Curevac | Pandemic PACT Tracker

Key facts

Disease
COVID-19
Known Financial Commitments (USD)
$15,300,000
Funder
Coalition for Epidemic Preparedness Innovations (CEPI)
Principal Investigator
N/A
Research Location
Germany
Lead Research Institution
Curevac
Research Priority Alignment
N/A

Research Category
Vaccines research, development and implementation
Research Subcategory
Phase 1 clinical trial
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Clinical Trial, Phase I
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified

Abstract

mRNA Full Length S stabilized (unmodified and codon optimized) Phase I safety and immunogenicity

Publicationslinked via Europe PMC

Last Updated:2 days ago

View all publications at Europe PMC

Retained Central Venous Catheter Guidewires: Interviews With Clinicians Who Have Made the Error.

Matrix-M adjuvant triggers inflammasome activation and enables antigen cross-presentation through induction of lysosomal membrane permeabilization.

Role of voltage-gated Ca<sup>2+</sup> channel dysfunction in gastric vagal afferent neuropathy following spinal cord injury.

The Wechsler intelligence scale for children, fourth and fifth editions perform comparably in children with Batten disease.

Iterative SCRaMbLE for engineering synthetic genome modules and chromosomes.

Hide-and-Seek genome editing reveals that Gephyrin is required for axo-axonic synapse assembly.

Menopausal hormone therapy is a risk factor for microscopic colitis: findings from a nationwide, matched case-control study.

Phosphatidic acid production on the vacuole harboring <i>Legionella pneumophila</i> is a signal for recognition of interferon-induced GTPases.

Positivity rates and subsequent patient dispositions after utilisation of cervical spine imaging referral guidelines in Singapore.